// App-Quantinova.ai

2127 : Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years

Researchers

Presenter

  • Laura Coates

Principal Investigators

  • Laure Gossec

  • Christine Contré

  • May Shawi

  • Emmanouil Rampakakis

  • Natalie Shiff

  • Alexa Kollmeier

  • Xie L Xu

  • Peter Nash

  • Philip J Mease

  • Philip Helliwell

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Sorbonne Universites, Paris, France

  • Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

  • Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA

  • Janssen Research & Development, San Diego, CA

  • Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

Locations

  • United Kingdom

  • France

  • United States

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

  • Uveitis

Biomarkers

  • C reactive protein

  • Malondialdehyde

  • Janus kinase

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved